Patent Assignment
Reel/Frame 042254/0349
Release of Security Interest
Recorded: 2017-04-14
Pages: 27
Assignor
U.S. BANK NATIONAL ASSOCIATION
Executed: 2017-04-13
Assignee
MERRIMACK PHARMACEUTICALS, INC.
ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE, MASSACHUSETTS, 02139
Covered Properties
(79)
Antibodies Against the Ectodomain of ERBB3 and Uses Thereof
Methods, Systems and Products for Predicting Response of Tumor Cells to a Therapeutic Agent and Treating a Patient According to the Predicted Response
Application:
14/148,379 →
Publication:
US 2014/0127238
Bispecific Binding Agents Targeting Igf-1R and ERBB3 Signalling and Uses Thereof
Application:
13/443,660 →
Publication:
US 2012/0244163
Use of Inhibitors of Egfr-Family Receptors in the Treatment of Hormone Refractory Breast Cancers
Application:
14/004,598 →
Publication:
US 2014/0134170
Use of ERBB3 Inhibitors in the Treatment of Triple Negative and Basal-Like Breast Cancers
Use of ERBB3 Inhibitors in the Treatment of Triple Negative and Basal-Like Breast Cancers
Antibodies Against Epidermal Growth Factor Receptor (Egfr) and Uses Thereof
Application:
14/847,351 →
Publication:
US 2015/0368361
Dosage and Administration for Preventing Cardiotoxicity in Treatment with ERBB2-Targeted Immunoliposomes Comprising Anthracyclin Chemotherapeutic Agents
Dosage and Administration for Preventing Cardiotoxicity in Treatment with ERBB2-Targeted Immunoliposomes Comprising Anthracycline Chemotherapeutic Agents
Application:
14/831,199 →
Publication:
US 2016/0038416
Dosage and Administration for Preventing Cardiotoxicity in Treatment with ERBB2-Targeted Immunoliposomes Comprising Anthracycline Chemotherapeutic Agents
Methods of Treatment of Tumors Expressing Predominantly High Affinity Egfr Ligands or Tumors Expressing Predominantly Low Affinity Egfr Ligands with Monoclonal and Oglioclonal Anti-Egfr Antibodies
Monoclonal and Oligoclonal Anti-Egfr Antibodies for Use in the Treatment of Tumors Expressing Predominantly High Affinity Egfr Ligands or Tumors Expressing Predominantly Low Affinity Egfr Ligands
Application:
14/833,834 →
Publication:
US 2016/0083800
Tandem Fc Bispecific Antibodies
Application:
14/185,628 →
Publication:
US 2014/0294834
Monospecific and Bispecific Anti-Igf-1R and Anti-ERBB3 Antibodies
Monospecific and Bispecific Anti-Igf-1R and Anti-ERBB3 Antibodies
Antibodies Against Epidermal Growth Factor Receptor (Egfr) and Uses Thereof
Antibodies Against Epidermal Growth Factor Receptor (Egfr) and Uses Thereof
Antibodies Against Epidermal Growth Factor Receptor (Egfr) and Uses Thereof
Antibodies Against Epidermal Growth Factor Receptor (Egfr) and Uses Thereof
Dosage and Administration of Monospecific and Bispecific Anti-Igr-1R and Anti-ERBB3 Antibodies
Application:
14/388,330 →
Publication:
US 2015/0231219
Compositions and Methods for Non-Invasive Imaging
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Marker Quantitation in Single Cells in Tissue Sections
Application:
14/409,808 →
Publication:
US 2015/0111217
Combination Therapy for Treating HER2-Positive Cancers
Non-Invasive Imaging Methods for Patient Selection for Treatment with Nanoparticulate Therapeutic Agents
Application:
14/181,583 →
Publication:
US 2014/0170075
ANTI-C-MET Tandem Fc Bispecific Antibodies
Methods and Compositions for Improving Outcomes of Liposomal Chemotherapy
Application:
14/783,619 →
Publication:
US 2016/0067182
Methods and Compositions for Improving Outcomes of Liposomal Chemotherapy
Application:
14/958,349 →
Publication:
US 2016/0184227
Biomarker Profiles for Predicting Outcomes of Cancer Therapy with ERBB3 Inhibitors and/or Chemotherapies
Dosage and Administration of Anti-IGF-1R, Anti-ErbB3 Bispecific Antibodies, Uses Thereof and Methods of Treatment Therewith
Application:
62/103,963 →
Dosage and Administration of Anti-Egfr Therapeutics
Combination Therapies for Treating HER2-Positive Cancers That Are Resistant to HER2-Targeted Therapies
Application:
14/819,317 →
Publication:
US 2016/0045596
Predicting Tumor Responses to Antibodies Against Hepatocyte Growth Factor (Hgf) and/or Its Cognate Receptor, C-Met
Application:
62/217,441 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And
Application:
62/265,409 →
Treatment of Breast Cancer with Liposomal Irinotecan
Application:
14/964,571 →
Publication:
US 2016/0346272
Methods for Improving the Pharmacokinetics and Therapeutic Index of Sustained Release Drug Therapies
Application:
62/147,389 →
Combination Treatments with Seribantumab
Application:
62/149,271 →
Methods of Treating Patients Having Mutations in the Extracellular Domain of Epidermal Growth Factor Receptor (Egfr) with a Combination of Three Fully Human Monoclonal Anti-Egfr Antibodies
Application:
62/244,991 →
Methods of Treating Patients Having Mutations in the Extracellular Domain of Epidermal Growth Factor Receptor (Egfr) with a Combination of Three Fully Human Monocolonal Anti-Egfr Antibodies
Application:
62/152,707 →
Combination Cancer Therapies
Application:
62/168,553 →
Combination of Cancer Therapies
Application:
62/245,825 →
Biomarkers for Predicting Outcomes of Cancer Therapy with ErbB3 Inhibitors and/or Chemotherapies
Application:
62/171,062 →
DOSAGE AND ADMINISTRATION OF ANTI-c-MET, ANTI-EpCAM BISPECIFIC ANTIBODIES, USES THEREOF AND METHODS OF TREATMENT THEREWITH
Application:
62/182,889 →
DOSAGE AND ADMINISTRATION OF ANTI-c-MET, ANTI-EpCAM BISPECIFIC ANTIBODIES, USES THEREOF AND METHODS OF TREATMENT THEREWITH
Application:
62/245,743 →
Combination Therapy for Cancer Treatment
Application:
62/207,709 →
Combination Therapy for Cancer Treatment
Application:
62/207,760 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
Application:
62/216,736 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
Application:
62/208,209 →
Combination Therapies for Treatment of Heregulin Positive Cancers
Application:
62/210,838 →
Liposomes with Improved Stability
Application:
62/242,835 →
Irinotecan liposomes with improved stability
Application:
62/244,061 →
Liposomes with Improved Stability
Application:
62/244,082 →
Liposomes with Improved Stability
Application:
62/242,873 →
Methods of Treating Cancer by Administering a Bispecific Antibody Antagonist of Igf-Ir and ERBB3 and a Combination of Anti-Egfr Antibodies
Application:
62/244,981 →
Methods of Treating Cancer by Administering a Mek Inhibitor and a Combination of Anti-Egfr Antibodies
Application:
62/244,941 →
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery to the Brain
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery to the Brain
Application:
14/151,632 →
Publication:
US 2014/0127136
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Application:
14/964,239 →
Publication:
US 2016/0081928
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Application:
14/879,358 →
Publication:
US 2016/0030342
Liposomes Useful for Drug Delivery
DISULFIDE-STABILIZED Fab FRAGMENTS
Application:
62/263,368 →
Bispecific Binding Agents for Modulating Biological Activity
Compositions and Methods for Delivering Nucleic Acid to a Cell
Application:
13/967,664 →
Publication:
US 2014/0065204
Antibodies Against ERBB3 and Uses Thereof
Antibodies Against the Ectodomain of ERBB3 and Uses Thereof
Antibodies Against ERBB3 and Uses Thereof
Methods and Systems for Predicting Response of Cells to a Therapeutic Agent
Antibodies Against Epidermal Growth Factor Receptor (Egfr) and Uses Thereof
Bispecific Anti-Igf-1R and Anti-ERBB3 Antibodies
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jun 15, 2012
From: BUKHALID, RAGHIDA; NIELSEN, ULRIK; WERNER, SHANNON; KEARNS, JEFFREY DAVID
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 028381/0296 →
Assignment of Assignor's Interest
Jun 19, 2012
From: MURUGANANDAM, ARUMUGAM; BUCKLER, DAVID
To: DYAX CORP.
Reel/Frame 028402/0568 →
Assignment of Assignor's Interest
Jun 19, 2012
From: SCHOEBERL, BIRGIT; NIELSEN, ULRIK; KUDLA, ARTHUR J.; LUGOVSKOY, ALEXEY ALEXANDROVICH
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 028402/0530 →
Assignment of Assignor's Interest
Sep 28, 2012
From: MOYO, VICTOR; GARCIA, GABRIELA
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 029043/0257 →
Assignment of Assignor's Interest
Sep 5, 2013
From: REYNOLDS, JOSEPH G.; OLIVIER, KENNETH J., JR.; HENDRIKS, BART S.; WICKHAM, THOMAS
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 031144/0967 →
Assignment of Assignor's Interest
Mar 11, 2014
From: HARMS, BRIAN; KOHLI, NEERAJ; LUGOVSKOY, ALEXEY; SU, STEPHEN
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 032403/0666 →
Assignment of Assignor's Interest
May 30, 2014
From: SCHOEBERL, BIRGIT; NIELSEN, ULRIK; GIBBONS, FRANCIS DAVID; ONSUM, MATTHEW DAVID
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 032997/0581 →
Assignment of Assignor's Interest
Jun 9, 2014
From: DYAX CORP.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 033058/0365 →
Assignment of Assignor's Interest
Jun 9, 2014
From: MURUGANANDAM, ARUMUGAM; BUCKLER, DAVID
To: DYAX CORP.
Reel/Frame 033058/0347 →
Assignment of Assignor's Interest
Jun 9, 2014
From: SCHOEBERL, BIRGIT; NIELSEN, ULRIK; FELDHAUS, MICHAEL
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 033058/0319 →
Assignment of Assignor's Interest
Jun 18, 2014
From: BAUM, JASON; JOHNSON, BRYAN; LUGOVSKOY, ALEXEY ALEXANDROVICH; XU, LIHUI
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 033125/0775 →
Assignment of Assignor's Interest
Oct 21, 2014
From: MOYO, VICTOR; GARCIA, GABRIELA
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 033988/0911 →
Assignment of Assignor's Interest
Oct 27, 2014
From: ADIMAB, LLC
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 034043/0657 →
Assignment of Assignor's Interest
Oct 27, 2014
From: FELDHAUS, MICHAEL; KRAULAND, ERIC
To: ADIMAB, LLC
Reel/Frame 034043/0635 →
Assignment of Assignor's Interest
Oct 27, 2014
From: BUKHALID, RAGHIDA; KING, ANNE; KOHLI, NEERAJ; KEARNS, JEFFREY DAVID
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 034043/0615 →
Assignment of Assignor's Interest
Dec 5, 2014
From: DYAX CORP.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 034395/0049 →
Assignment of Assignor's Interest
Dec 5, 2014
From: SCHOEBERL, BIRGIT; NIELSEN, ULRIK; FELDHAUS, MICHAEL
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 034395/0001 →
Assignment of Assignor's Interest
Dec 5, 2014
From: MURUGANANDAM, ARUMUGAM; BUCKLER, DAVID
To: DYAX CORP.
Reel/Frame 034395/0034 →
Assignment of Assignor's Interest
Aug 25, 2015
From: BUKHALID, RAGHIDA; NIELSEN, ULRIK; WERNER, SHANNON; KEARNS, JEFFREY DAVID
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 036408/0577 →
Assignment of Assignor's Interest
Sep 29, 2015
From: BAUM, JASON; JOHNSON, BRYAN; LUGOVSKOY, ALEXEY ALEXANDROVICH; XU, LIHUI
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 036685/0853 →
Assignment of Assignor's Interest
Oct 1, 2015
From: HARMS, BRIAN; KOHLI, NEERAJ; LUGOVSKOY, ALEXEY; SU, STEPHEN
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 036705/0343 →
Assignment of Assignor's Interest
Nov 11, 2015
From: DYAX CORP.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 037014/0259 →
Assignment of Assignor's Interest
Nov 20, 2015
From: BUKHALID, RAGHIDA; KING, ANNE; KOHLI, NEERAJ; KEARNS, JEFFREY DAVID
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 037103/0925 →
Assignment of Assignor's Interest
Nov 20, 2015
From: ADIMAB, LLC
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 037103/0972 →
Assignment of Assignor's Interest
Nov 20, 2015
From: ADIMAB, LLC
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 037103/0956 →